Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Venetolax plus azacitidine is effective maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with intermediate/high-risk Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

XXXiaoxuan Xu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows maintenance therapy decreases relapse rates in AML patients after transplant, suggesting vital implications for treatment strategies.

Key Points

  • Cumulative incidence of relapse was significantly lower at 8.7% in the azacitidine group compared to 37.3% in controls.
  • Overall survival at three years was improved to 94.1% for the azacitidine group versus 61.3% for controls.
  • Patients received maintenance therapy beginning three months post-transplant, demonstrating clear benefits.
  • Results support the use of azacitidine in managing relapse risks for intermediate/high-risk AML patients post-transplant.

Cite This Study

Xiaoxuan Xu (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d37chttps://doi.org/10.1182/blood-2025-6995
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation2025
  2. 2Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation2025
  3. 3Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  4. 4Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party2025
  5. 5Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand2025 · 2 citations